PPARG and autosomal dominant polycystic kidney disease: PPARγ agonists have also been reported to dampen kidney damage in several experimental models such as ischemia reperfusion injury, autosomal dominant polycystic kidney disease (ADPKD), and nondiabetic chronic kidney diseases [9].